|
|
|
11-50 employees
View all
|
|
Biotechnology
|
|
300 George Street, Suite 530, New Haven, CT 06511, US
|
|
Kolltan, a privately held clinical-stage company, is focused on advancing a new generation of therapeutics in oncology and other diseases by discovering and developing novel biologic agents designed to modulate the function of receptor tyrosine kinases (RTKs). Kolltan is led by an experienced team of executives and scientists with a deep understanding of RTKs, their ligands, and cellular signaling. Located adjacent to the Yale Medical School in New Haven, Connecticut, Kolltan is working in close collaboration with the laboratory of Kolltan co-founder, Dr. Joseph Schlessinger, as well as the Yale medical and scientific community to bring important medicines to cancer patients and other patients with serious diseases. The Company's R&D pipeline is advancing rapidly, with the first clinical trial initiated in January 2014.
|
Kolltan Pharmaceuticals, Inc. Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
66.67%
|
The widely used Kolltan Pharmaceuticals, Inc. email format is {first}.{last} (e.g. [email protected]) with 66.67% adoption across the company.
To contact Kolltan Pharmaceuticals, Inc. customer service number in your country click here to find.
Carmela Senese is the CEO of Kolltan Pharmaceuticals, Inc.. To contact Carmela Senese email at [email protected].
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.